NO337128B1 - Anvendelse av en kombinasjon av R,R-glykopyrrolat og et langtidsvirkende β2-mimetisk middel for fremstilling av et medikament for behandling av respiratoriske sykdommer og fremgangsmåte for fremstilling av et farmasøytikum - Google Patents

Anvendelse av en kombinasjon av R,R-glykopyrrolat og et langtidsvirkende β2-mimetisk middel for fremstilling av et medikament for behandling av respiratoriske sykdommer og fremgangsmåte for fremstilling av et farmasøytikum Download PDF

Info

Publication number
NO337128B1
NO337128B1 NO20063882A NO20063882A NO337128B1 NO 337128 B1 NO337128 B1 NO 337128B1 NO 20063882 A NO20063882 A NO 20063882A NO 20063882 A NO20063882 A NO 20063882A NO 337128 B1 NO337128 B1 NO 337128B1
Authority
NO
Norway
Prior art keywords
glycopyrrolate
treatment
acceptable salts
formoterol
physiologically acceptable
Prior art date
Application number
NO20063882A
Other languages
English (en)
Norwegian (no)
Other versions
NO20063882L (no
Inventor
Istvan Szelenyi
Joachim Goede
Joachim Maus
Peter Jürgen Cnota
Original Assignee
Meda Pharma Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meda Pharma Gmbh & Co Kg filed Critical Meda Pharma Gmbh & Co Kg
Publication of NO20063882L publication Critical patent/NO20063882L/no
Publication of NO337128B1 publication Critical patent/NO337128B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
NO20063882A 2004-02-06 2006-08-31 Anvendelse av en kombinasjon av R,R-glykopyrrolat og et langtidsvirkende β2-mimetisk middel for fremstilling av et medikament for behandling av respiratoriske sykdommer og fremgangsmåte for fremstilling av et farmasøytikum NO337128B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54195704P 2004-02-06 2004-02-06
PCT/EP2005/000649 WO2005074900A2 (en) 2004-02-06 2005-01-24 NOVEL COMBINATION OF ANTICHOLINERGIC AND β MIMETICS FOR THE TREATMENT OF RESPIRATORY DISEASES

Publications (2)

Publication Number Publication Date
NO20063882L NO20063882L (no) 2006-10-26
NO337128B1 true NO337128B1 (no) 2016-01-25

Family

ID=34837534

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063882A NO337128B1 (no) 2004-02-06 2006-08-31 Anvendelse av en kombinasjon av R,R-glykopyrrolat og et langtidsvirkende β2-mimetisk middel for fremstilling av et medikament for behandling av respiratoriske sykdommer og fremgangsmåte for fremstilling av et farmasøytikum

Country Status (19)

Country Link
US (3) US20050175549A1 (enExample)
EP (1) EP1718336B1 (enExample)
JP (1) JP5524442B2 (enExample)
CN (1) CN1905902A (enExample)
AT (1) ATE399027T1 (enExample)
AU (1) AU2005210083B2 (enExample)
CA (1) CA2550841C (enExample)
CY (1) CY1108326T1 (enExample)
DE (1) DE602005007708D1 (enExample)
DK (1) DK1718336T3 (enExample)
ES (1) ES2309705T3 (enExample)
HR (1) HRP20080439T3 (enExample)
NO (1) NO337128B1 (enExample)
NZ (1) NZ548302A (enExample)
PL (1) PL1718336T3 (enExample)
PT (1) PT1718336E (enExample)
RU (1) RU2438660C2 (enExample)
SI (1) SI1718336T1 (enExample)
WO (1) WO2005074900A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
WO2005074918A1 (en) * 2004-02-06 2005-08-18 Benzstrasse 1 D-61352 Bad Homburd The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
ES2389231T3 (es) * 2005-12-21 2012-10-24 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos, glucocorticoides y agonistas de beta2 para el tratamiento de enfermedades inflamatorias
US20080031828A1 (en) * 2006-08-03 2008-02-07 Boehringer Ingelheim International Gmbh Method for the Treatment of Dyspnea Comprising Combined Administration of Tiotropium Salts and Salts of Salmeterol
EP1944018A1 (en) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
NZ587561A (en) * 2008-02-26 2012-10-26 Elevation Pharmaceuticals Inc Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations (an muscarinic antagnoist)
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2221048A1 (en) 2009-02-18 2010-08-25 Siegfried Generics International AG Pharmaceutical composition for inhalation
EP3106149B1 (en) * 2009-05-29 2019-11-20 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta-2 adrenergic receptor agonists and associated methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US20110132355A1 (en) * 2009-06-09 2011-06-09 William Gerhart Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
CA2785349C (en) * 2009-12-23 2018-07-03 Chiesi Farmaceutici S.P.A. Combination therapy for copd
WO2011076842A2 (en) * 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Aerosol formulation for copd
BR112012015335B1 (pt) * 2009-12-23 2021-05-18 Chiesi Farmaceutici S.P.A. formulação de aerossol para doença pulmonar obstrutiva crõnica
RS53391B2 (sr) * 2009-12-23 2023-09-29 Chiesi Farm Spa Kombinovana terapija copd-a (hroničnih obstruktivnih bolesti pluća)
RU2013142268A (ru) 2011-02-17 2015-03-27 Сипла Лимитед Фармацевтическая композиция
JO3510B1 (ar) * 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
BR112013029507A2 (pt) * 2011-05-17 2019-09-24 Pearl Therapeutics Inc método para tratar uma doença ou um distúrbio
BR112015022784B1 (pt) 2013-03-15 2023-02-14 Pearl Therapeutics, Inc Método de condicionamento de material cristalino micronizado e sistemas de condicionamento
DK3089735T3 (en) * 2013-12-30 2018-09-17 Chiesi Farm Spa STABLE PRESSURE AEROSOL SOLUTION COMPOSITION OF GLYCOPYRRONIUM BROMIDE AND FORMOTEROL COMBINATION
CN105848642A (zh) * 2013-12-30 2016-08-10 奇斯药制品公司 格隆溴铵和福莫特罗组合的稳定的加压气雾剂溶液组合物
WO2017077488A1 (en) * 2015-11-04 2017-05-11 Glenmark Pharmaceuticals Limited An inhalable fixed dose powder composition comprising glycopyrronium and formoterol
CA3152578A1 (en) 2019-12-02 2021-06-10 Enrico Zambelli Stainles steel can for pressurised metered dose inhalers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115681A1 (en) * 1999-05-12 2002-08-22 Karl-Heinz Bozung Medicament compositions containing anticholinergically-effective compounds and salmeterol
US6645466B1 (en) * 1998-11-13 2003-11-11 Jago Research Ag Dry powder for inhalation
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000016A1 (en) * 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
EP1369414A1 (de) 1996-11-11 2003-12-10 Christian R. Noe Enantiomerenreine Arylcycloalkyl-Hydroxycarbonsäureester, Verfahren zu ihrer Herstellung und ihre Verwendung als Muskarinrezeptor-Modulatoren
US6585958B1 (en) 1998-07-24 2003-07-01 Jago Research Ag Medicinal aerosol formulations
DK1102579T3 (da) * 1998-08-04 2003-07-14 Jago Res Ag Medicinske aerosolformuleringer
DE19961300A1 (de) * 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0008485D0 (en) * 2000-04-07 2000-05-24 Glaxo Group Ltd Pharmaceutical compositions
US20040101483A1 (en) * 2001-03-30 2004-05-27 Rudi Muller-Walz Medical aerosol formulations
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645466B1 (en) * 1998-11-13 2003-11-11 Jago Research Ag Dry powder for inhalation
US20020115681A1 (en) * 1999-05-12 2002-08-22 Karl-Heinz Bozung Medicament compositions containing anticholinergically-effective compounds and salmeterol
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics

Also Published As

Publication number Publication date
RU2006132036A (ru) 2008-03-20
US7985766B2 (en) 2011-07-26
SI1718336T1 (sl) 2008-10-31
PL1718336T3 (pl) 2008-11-28
EP1718336B1 (en) 2008-06-25
WO2005074900A3 (en) 2006-04-06
AU2005210083A1 (en) 2005-08-18
AU2005210083B2 (en) 2010-03-11
JP2007520506A (ja) 2007-07-26
CN1905902A (zh) 2007-01-31
DK1718336T3 (da) 2008-10-20
CA2550841C (en) 2012-10-02
NO20063882L (no) 2006-10-26
NZ548302A (en) 2010-04-30
PT1718336E (pt) 2008-08-28
CY1108326T1 (el) 2014-02-12
RU2438660C2 (ru) 2012-01-10
ES2309705T3 (es) 2008-12-16
HRP20080439T3 (hr) 2008-10-31
US20070270481A1 (en) 2007-11-22
ATE399027T1 (de) 2008-07-15
WO2005074900A2 (en) 2005-08-18
DE602005007708D1 (de) 2008-08-07
CA2550841A1 (en) 2005-08-18
EP1718336A2 (en) 2006-11-08
US20060252815A1 (en) 2006-11-09
JP5524442B2 (ja) 2014-06-18
US20050175549A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
US7985766B2 (en) Combination of anticholineric and β mimetics for the treatment of respiratory diseases
US20020052312A1 (en) Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
HUP0200083A2 (en) Pharmaceutical composition containing combinations of formoterol and a tiotropium salt and their use
JP2013075909A (ja) フォルモテロールを含むエアゾール
CN102724974A (zh) 毒蕈碱受体拮抗剂和β-2肾上腺素受体激动剂的组合
AU2012266541A1 (en) Combination comprising umeclidinium and a corticosteroid
ES2300755T3 (es) Combinacion sinergica que comprende roflumilast y un agente anticolinergico seleccionado de sales de tiotropio para el tratamiento de enfermedades respiratorias.
CA2688542C (en) Methods and compositions for administration of oxybutynin
KR20010032009A (ko) 수면성 무호흡의 치료에 미타자핀을 사용하는 방법
WO2004084897A1 (en) Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
NO334247B1 (no) Medikament omfattende roflumilast i kombinasjon med formoterol
AU2003288169B2 (en) Synergistic combination comprising roflumilast and (R,R) -formoterol
JP2016504358A (ja) オキシブチニンを投与するための方法および組成物
WO2004084894A1 (en) Synergistic combination comprising roflumilast and revatropate for the treatment of respiratory diseases
MXPA06008936A (en) NOVEL COMBINATION OF ANTICHOLINERGIC AND beta MIMETICS FOR THE TREATMENT OF RESPIRATORY DISEASES
HK1098355A (en) NOVEL COMBINATION OF ANTICHOLINERGIC AND β MIMETICS FOR THE TREATMENT OF RESPIRATORY DISEASES
TW201605440A (zh) 阿地銨之新用途

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees